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Abstract
	 Background:	The	prevalence	of	metabolic	syndrome	(MetSyn)	is	increasing	worldwide.	The	
aim	of	this	study	was	to	determine	the	prevalence	of	MetSyn	and	insulin	resistance	(IR)	in	children	
and	adolescents	in	Qazvin,	Iran.	
	 Methods: A	cross-sectional	study	was	conducted	in	338	children	and	adolescents	aged	10–
18	years	old	who	were	selected	by	a	multistage	cluster	random	sampling	method.	We	performed	
standardised	 measurements	 of	 variables	 including	 waist	 circumference	 (WC),	 blood	 pressure,	
plasma	 glucose	 level,	 total	 cholesterol,	 high-density	 lipoprotein	 cholesterol	 (HDL),	 triglycerides,	
and	insulin.	MetSyn	was	defined	according	to	the	International	Diabetes	Federation	criteria.	IR	was	
estimated	by	the	homeostatic	model	assessment.	
	 Results: Of	the	338	total	subjects,	172	were	female.	The	overall	prevalence	of	MetSyn	and	IR	
were	3.4%	and	18.2%,	respectively.	There	was	no	sex	difference	for	the	prevalence	of	MetSyn.	A	total	
of	185	subjects	(56.4%)	had	one	or	two	components	of	MetSyn.	The	most	common	component	was	
low	HDL	levels	in	both	sexes,	which	was	followed	by	high	WC	in	females	and	high	fasting	plasma	
glucose	levels	in	males.	
	 Conclusion: The	lack	of	a	standard	definition	of	MetSyn	in	children	and	adolescents	combined	
with	the	geographical	and	socioeconomic	differences	make	it	difficult	to	compare	the	results	from	
different	studies.	Modification	of	lifestyle	habits	is	an	important	strategy	in	preventing	MetSyn	and	
IR.
Keywords:	adolescent,	body	mass	index,	insulin	resistance,	Metabolic	Syndrome	X
Introduction
 According to the World Health Organization 
(WHO), 75% of all deaths in developing countries 
will be due to non-communicable diseases by the 
year 2020 (1). Metabolic syndrome (MetSyn), 
a well-recognised risk factor of cardiovascular 
disorders and diabetes mellitus (2), is a cluster of 
metabolic abnormalities that includes impaired 
glucose metabolism, atherogenic dyslipidaemia, 
abdominal obesity and hypertension.
 The worldwide prevalence of MetSyn has 
increased in the last few decades. In a study 
among 1 844 Chinese children (7 to 14 years old), 
the prevalence of overweight, obesity, and MetSyn 
was 11%, 7.2% and 6.6%, respectively (3). In Iran, 
Kelishadi et al. reported an increase in obesity 
and a 14% prevalence of MetSyn (4). 
 MetSyn is not a disease by itself, rather it 
is a set of undesirable characteristics that are 
associated with habits, unhealthy lifestyle, and 
obesity. Recent evidence suggests that modern 
lifestyles and lack of activities are the main 
causes of the increasing obesity trend. Childhood 
obesity is a key component of MetSyn and insulin 
resistance (IR) (5). Furthermore, MetSyn and IR 
are major predisposing factors for type 2 diabetes 
mellitus (6).
 Although adulthood is the main window 
for the onset of atherosclerotic cardiovascular 
symptoms, it has been shown that the processes 
resulting in these symptoms begin in childhood. 
Early diagnosis of MetSyn and IR with appropriate 
interventions can lead to better prevention 
and control of type 2 diabetes mellitus and 
cardiovascular diseases (7).
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 The reported prevalence of MetSyn provides 
inconsistent estimates that cannot be generalised. 
Additionally, limited reports are available on 
the prevalence of IR in children and adolescents 
in Iran. To address this problem, the aim of this 
study was to determine the prevalence of these 
two conditions in children and adolescents (10 to 
18 years old) in Qazvin, Iran. 
Methods
Subjects
 This cross-sectional study was carried out 
in children and adolescents (10 to 18 years old) 
from the Mindoodar district of Qazvin, Iran, from 
September to November 2011. Qazvin is located 
in the northwest of Iran. The methods were in 
agreement with the Declaration of Helsinki and 
were approved by the ethics committee of Qazvin 
University of Medical Sciences. All households 
of the Mindoodar district had health files at the 
Mindoodar Health Center and thesampling unit 
was the household. The Mindoodar district was 
divided into four geographical divisions that were 
similar and homogeneous in terms of population 
size. Each division was considered a cluster. 
Therefore, four main clusters were identified 
in this district. The subjects were selected by 
multistage cluster random sampling method. 
Owning an apartment and residence for at least 
the next 5 years in the area were inclusion criteria. 
Children and adolescents (10 to 18 years old) and 
their parents were invited to the study. Children 
and adolescents with an inflammatory disease 
and those who were taking anti-inflammatory 
medicines were excluded. The sample size was 
calculated using this formula:
 Considering Z as the statistic corresponding 
to the level of confidence, α: 0.05, precision (d): 
5%, and prevalence of MetSyn (P): 14% (4), the 
calculated sample size (n) was 186. However, 
338 subjects were selected to increase the study 
power. Written informed consent was obtained 
from both parents and participants.
Data	collection
 Demographic information was collected 
by a general practitioner using a self-reported 
questionnaire. Adolescents (12 to 18 years old) 
completed the questionnaire by themselves and 
parents completed it for children (< 12 years old). 
All anthropometric and laboratory measurements 
were performed after 12 hours of fasting. Weight 
was measured by a Seca scale (Germany) with a 
sensitivity as low as 0.1 kg. A tape measure with 
an accuracy of 0.5 cm was used to measure the 
height in a barefoot standing position. The waist 
circumference (WC) was measured halfway 
between the costal margin and the iliac crest and 
at the end of a normal expiration. Body mass index 
(BMI) was estimated as weight (kg) divided by the 
height (m) squared. On a single occasion, blood 
pressure (BP) was measured twice following a 10 
minutes rest. A mercury sphygmomanometer was 
used to measure BP in a seated position. The BP 
measurement was performed twice with at least 
a 10 minutes interval between measures and the 
mean value was used as their BP in the analysis. 
All physical examinations were performed by a 
paediatrician.
 A venous blood sample was taken from 
all subjects. The samples were analysed in a 
regional certified medical laboratory. Fasting 
plasma glucose (FPG), insulin, triglycerides 
(TGs), total cholesterol, low density lipoprotein 
(LDL) cholesterol, high density lipoprotein 
(HDL) cholesterol and C-reactive protein (CRP) 
were measured. Insulin levels were measured by 
the ELISA method using a reagent (Monobind 
Company, USA) with a within-run precision 
coefficient of variation (CV) of 4.9 and a total 
precision CV of 4.9. An oral glucose tolerance test 
(OGTT) with 75 g of glucose was performed on 
subjects without a previous diagnosis of diabetes. 
 FPG levels were measured by a Hitachi 704 
auto-analyzer using the GOD-PAP method and 
reagent (Parsazmun Company, Tehran, Iran); 
mean intra- and interassay CVs were 1.28 and 
0.84, respectively. Insulin levels were measured 
by the ELISA method using a reagent (Monobind 
Company, USA) with a within-run precision CV 
of 4.9 and a total precision CV of 4.9. TGs were 
measured with a Hitachi 704 auto-analyzer using 
GPO-PAP and reagent (Parsazmun Company); 
mean intra- and interassay CVs were 1.82 and 
1.04, respectively. Cholesterol was measured by a 
Hitachi 704 auto-analyzer using CHOD-PAP and 
reagent (Parsazmun Company); mean intra- and 
interassay CVs were 0.61 and 1.22, respectively. 
To measure LDL and HDL levels, a Hitachi 704 
auto-analyzer with immunoturbidimetric and 
reagent (Parsazmun Company) was used; mean 
intra- and interassay CVs for LDL were 0.63 and 
1.29, respectively, and for HDL they were 0.73 
and 1.8, respectively.
34 www.mjms.usm.my
Malays J Med Sci. Nov-Dec 2015; 22(6): 32-39
Definitions
 Overweight was defined as having a BMI 
between the 85th and the 95th percentiles for 
age and sex. BMI levels over the 95th percentile 
for age and sex were considered as obesity 
(8). MetSyn was defined according to the 
International Diabetes Federation (IDF) criteria 
(9). Specifically, from the ages of 10 to 16 years, 
a subject was considered to have MetSyn when at 
least three of the following five components were 
present: 1) WC > 90th percentile; 2) TGs > 150 
mg/dL; 3) HDL < 40 mg/dL; 4) systolic BP > 130 
mmHg or diastolic BP > 85 mmHg; and 5) FPG > 
100 mg/dL or previously diagnosed with type 2 
diabetes mellitus. For a MetSyn determination in 
ages older than 16 years, subjects needed to have 
central obesity (WC > 94 cm in boys and WC > 
80 cm in girls) with any two of the following four 
components: 1) TGs: > 150 mg/dL or treatment 
for hypertriglyceridemia; 2) HDL < 40 mg/dL in 
males and < 50 mg/dL in females, or treatment 
for this condition; 3) systolic BP > 130 mmHg 
or diastolic BP > 85 mmHg, or treatment for 
hypertension; and 4) FPG > 100 mg/dL, or 
previously diagnosed with type 2 diabetes. IR was 
determined by the homeostatic model assessment 
(HOMA-IR). HOMA-IR was calculated as fasting 
serum insulin (μIU/mL) × fasting plasma glucose 
(mmol/L)/22.5 (10). The HOMA-IR cut-off point 
for the diagnosis of IR was 2.5 (10).
Data	analysis
 The Kolmogorov-Smirnov test was used to 
examine the normality of each variable. Data are 
described as mean (standard deviation (SD)), 
median (minimum – maximum), or frequency 
(percent). Anthropometric and biochemical 
measurements were compared between males and 
females using t tests or Mann-Whitney U tests, 
where appropriate. The prevalence of MetSyn 
components (high WC, high TGs, low HDL, high 
BP, and high FPG) was compared between males 
and females using the chi square test. IR was 
considered as the gold standard. Sensitivity and 
specificity of MetSyn for IR diagnoses were also 
calculated as shown below.
 Sensitivity = true positive/(true positive + 
false negative)
 Specificity = true negative/(true negative + 
false positive)
 P values of less than 0.05 were considered 
statistically significant. All of the analyses were 
performed using SPSS software version 22 (SPSS, 
Inc., Chicago, IL, USA).
Results
 In terms of sexes, from a total of 338 subjects, 
females accounted for 50.1% of all participants. 
Anthropometric and biochemical characteristics 
of the subjects are shown in Table 1. Systolic and 
diastolic BP and FPG were significantly different 
between males and females. A total of 287 subjects 
(84.9%) had normal weights, 35 (10.4%) were 
overweight and 16 (4.7%) were obese.
 The overall prevalence of MetSyn was 3.4%. 
There was no sex difference for the prevalence of 
MetSyn (6 [3.8%] in males vs 5 [3%] in females; P 
= 0.081). The prevalence of IR was 18.2% overall. 
The sex difference for the prevalence of IR was 
not statistically significant (23 [14.4%] in males vs 
37 [21.9%] in females; P = 0.087). The sensitivity 
and specificity of MetSyn for the diagnosis of IR 
was 10.34% and 98.13%, respectively.
 The frequencies of the various MetSyn 
components are shown in Table 2. A total of 185 
subjects (56.4%) had 1 to 2 MetSyn components, 
however, none of the subjects had all of the 
components.
 The prevalences of MetSyn risk factors are 
shown in Table 3. The most common component 
in both sexes was low HDL. The second most 
common component was high WC in females and 
high FPG in males. The prevalence of high WC and 
low HDL was significantly different with regard to 
the sexes. 
Discussion
 MetSyn is mainly related to the development 
of cardiovascular disease and diabetes mellitus, 
and has been turned into a modern worldwide 
epidemic (11). The presence of each component 
of MetSyn during childhood is an important 
predictive tool for adulthood diseases. It is 
important to continually monitor the trends of 
cardiovascular risk factors, MetSyn and IR. In the 
present study, the prevalence of MetSyn was 3.4% 
according to IDF criteria, however, the prevalence 
of IR was about five times more than MetSyn.
 The reported prevalence of MetSyn has been 
inconsistent in previous studies. In Iran, Salem 
and Vazirinejad (12) reported a prevalence of 
3.9% for MetSyn among 4,246 girls aged 11–18 
years in Rafsanjan, which was similar to the 
results observed in the present study; however, 
the prevalence of MetSyn was 14% in a study by 
Isfahan (4). Cook et al. (13) reported the MetSyn 
prevalence as 4.2% among 12 to 19 years old in 
the U.S. population, while de Ferranti et al. (14) 
reported a prevalence of 9.2% among American 
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Table	1:	Anthropometric and biochemical characteristics of the study subjects by gender
Total Male Female P-value
Agea 15.10 (2.43) 15.00 (2.43) 15.18 (2.42) 0.233c
Body mass index 
(kg/m2)
19.86 (4.08) 19.72 (3.96) 19.91 (4.10) 0.400c
Waist circumference 
(Cm)
72.76 (9.87) 73.56 (10.07) 72.08 (9.63) 0.241c
Systolic blood 
pressure (mmHg)
103.05 (14.99) 105.05 (16.18) 101.13 (13.52) 0.020c
Diastolic blood 
pressure (mmHg)
63.74 (9.87) 65.18 (9.94) 62.36 (9.62) 0.003c
Fasting plasma 
glucose (mg/dl)
86.69 (11.05) 88.06 (12.08) 84.77 (9.93) 0.028c
Blood glucose after 2 
h (mg/dl)
93.04 (17.12) 92.01 (15.26) 92.5 (17.74) 0.774c
Insulin (μIU/ml)b 0.7 (0.1-126.1) 0.5 (0.1-85.7) 0.7 (0.1-126.1) 0.228d
HOMAIRb 0.148 (0.02-26.93) 0.138 (0.02-23.15) 0.156 (0.02-26.93) 0.381d
Triglycerides (mg/
dl)b
85 (34.5-753) 86 (35-288) 83 (34.5-753) 0.768d
Cholesterol (mg/dl) 152.07 (29.62) 150.75 (28.36) 152.36 (30.57) 0.128c
LDL (mg/dl) 88.57 (21.35) 87.65 (21.51) 89.94 (21.7) 0.227c
HDL (mg/dl) 41.45 (8.33) 40.55 (8.00) 41.83 (8.64) 0.096c
C-reactive protein 
(mg/dl)b
0.25 (0-8.85) 0.27 (0-8.85) 0.25 (0.01-5.2) 0.819d
aMean (SD); bMedian (minimum-maximum); c t test; dMann Whitney U test.
Table	2: Frequency of Metabolic Syndrome components in the study subjects
Number	of	components Frequency	(%)
Total Male Female
0 132 (40.20) 72 (45.30) 60 (35.50)
1 144 (43.90) 68 (42.80) 76 (45.00)
2 41 (12.50) 13 (8.20) 28 (16.60)
3 10 (3.00) 5 (3.10) 5 (3.00)
4 1 (0.30) 1 (0.60) 0
5 0 0 0
Table	3: Prevalence of metabolic syndrome components in the study subjects by gender
Frequency	(percent)
P	valuea	
Total Male Female
High waist circumference 32 (9.50) 8 (4.90) 24 (14.00) 0.005
High triglycerides 36 (10.90) 17 (10.50) 19 (11.20) 0.861
Low HDL 154 (46.70) 65 (40.40) 89 (52.70) 0.028
High blood pressure 10 (3.00) 6 (3.60) 4 (2.30) 0.536
High fasting plasma glucose  29 (8.80) 18 (11.10) 11 (6.50) 0.174
aChi square test.
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teenagers. Furthermore, according to 2005 
report, the prevalence of MetSyn was 10–15% in 
China, Taiwan, Hong Kong, and Thailand (15). 
 The lack of a standard MetSyn definition and 
non-uniform cut-off points for anthropometric 
measurements, lipid levels, blood pressure and 
glucose, in various definitions have resulted 
in differing reported prevalence rates for this 
syndrome. Therefore, it is difficult to compare 
the prevalence of MetSyn between studies. In a 
systematic review by Friend et al. in the paediatric 
population, the MetSyn prevalence was 3–10% 
based on ATP criteria and 1–7% based on IDF 
criteria (16). The lowest MetSyn prevalence was 
related to studies in Europe and Asia (3.3–4.2%), 
while the highest prevalence rates were for the 
Middle East and North America (4.2%–10%) (16).
 The MetSyn prevalence was not significantly 
different with regards to sex in the present study. 
Likewise, in the Daratha and Bindler (17) and 
Santos et al. (18) studies, the difference in MetSyn 
prevalence was not significant with regard to sex, 
however, in the Mar Bibiloni et al. (19) study, the 
MetSyn prevalence in adolescent boys was more 
than that observed in girls.
 MetSyn is associated with obesity and 
being overweight. Obesity is a risk factor for IR, 
hyperinsulinemia, type 2 diabetes, cardiovascular 
disease, hypertension and dyslipidaemia (20). In 
a study by Guzmán-Guzmán et al., the MetSyn 
prevalence was 44.3% in the obese group and 
0.84% in normal-weight children (21). In the 
Saffari et al. study, MetSyn was present in 50% 
of the overweight and 66.2% of the obese subjects 
based on NCEP ATP III criteria (22). The low 
MetSyn prevalence in the present study may be 
the result of the low prevalence of obesity. It seems 
that the best way to reduce the risk of MetSyn is to 
prevent obesity.
 In the present study, despite the low 
prevalence of MetSyn, 56.4% of the subjects 
had one or two components of MetSyn. In the 
Esmaillzadeh et al. study, 58.8% of adolescents 
had one or two components of MetSyn, which 
was similar to the present study (23). Guzmán-
Guzmán et al. showed that one third of children 
with normal weight had one component of MetSyn 
(21). The presence of as few as three components 
may serve as a warning signal about the future 
risk of MetSyn.
 The most common component of MetSyn 
was low HDL levels, regardless of the sex; this 
was followed by high WC in females in the present 
study. In Mexican children, impaired glucose and 
low HDL were the most frequent abnormalities in 
the normal-weight group (21). In China, the most 
frequent component was also low HDL levels 
(24). Park et al. conducted a study in both Korean 
and American adolescents (25). They found that 
the most common metabolic disorders in U.S. 
adolescents are abdominal obesity and low HDL, 
while the most common in Korean adolescents 
are low HDL and abdominal obesity. Kelishadi 
performed a review among children and adults 
and concluded that high TGs and low HDL were 
the most common components of MetSyn in Iran 
and Turkey (26). It has been shown that diets 
rich in saturated fats and trans-fatty acids are 
correlated with a high prevalence of dyslipidaemia 
among Iranian adolescents (26).
 IR is a predisposing factor of type 2 diabetes 
that begins in childhood and it is not benign. IR 
does not always lead to diabetes; however, it is a 
main risk factor of other complications including 
atherosclerosis, high blood pressure, obesity, 
acanthosis nigricans, dyslipidaemia, polycystic 
ovarian syndrome, fatty liver, and higher cancer 
rates (7). 
 IR prevalence was 18.2% in the present study. 
In a study by Goodman et al., hyperinsulinemia 
was defined as the top quartile of insulin among 
non-diabetic subjects (27). This cross-sectional 
study was conducted in 1 513 black, white, and 
Hispanic 12–18 year-old teens, and the prevalence 
of hyperinsulinemia was 25% (27). In another 
study from Quebec, Canada, the estimated 
prevalence of IR syndrome was as high as 11.5% 
(95% CI: 10.2–12.9) in children and adolescents 
(28). Genetic and environmental factors may 
be associated with ethnic differences in IR. IR 
increases during puberty and its levels remain 
higher in adulthood than pre-pubertal levels (27). 
Part of the IR prevalence in the present study is 
attributable to the transient physiological IR of 
puberty. However, the association of pubertal IR 
and the development of MetSyn is unknown (27).
 IR and MetSyn are closely linked. Although 
IR may have a central role in the pathogenesis of 
MetSyn, it is not sufficient for the development 
of the syndrome. Other factors are involved in 
the pathophysiology underlying MetSyn (29). 
Dyslipidaemia, especially hypertriglyceridemia, 
and low HDL, are strongly associated with IR 
and are also components of MetSyn. It is unclear 
whether IR develops lipid abnormalities or 
whether IR and lipid abnormalities are associated 
through other factors (29). However, puberty 
may be the main contributing factor for the IR 
prevalence observed in the present study, and the 
role of IR as a main underlying cause of MetSyn 
should also be considered.
 The prevalence of MetSyn and IR is related to 
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a sedentary lifestyle in the modern world. Lifestyle 
modifications for sleep habits (30, 31) nutritional 
habits and physical activity could considerably 
reduce the risk of cardiovascular disease and 
diabetes. It has been shown that increased 
consumption of whole grain foods improves 
insulin sensitivity in adults (32). Exercise also 
influences improvements in insulin sensitivity, 
HDL levels, glucose levels and blood pressure 
(32).
 One of the strengths of this study is the 
availability of a homogenous population in Qazvin 
province. A potential limitation of the present 
study is its cross-sectional design. There is also 
no consensus about which criteria of MetSyn to 
use. Other criteria may be more appropriate than 
the IDF criteria for the diagnosis of MetSyn in 
children and adolescents.
Conclusion
 The prevalence of MetSyn was 3.4% in the 
10–18 yearsold population in Qazvin. The lack 
of a standard definition of MetSyn in children 
and adolescents, as well as the geographical and 
socioeconomic differences, make it difficult to 
compare different results. While part of the IR 
prevalence in the present study is attributable to the 
transient physiological IR of puberty, it also shows 
the future burden of type 2 diabetes and MetSyn. 
Therefore, screening of children susceptible to IR 
is necessary. Lifestyle modifications are important 
strategies for preventing MetSyn and IR. Further 
studies are needed to investigate the risk factors 
of IR. 
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